Vol. 2 No. 7 (2022)
Reimbursement Recommendations

Lisocabtagene Maraleucel (Breyanzi)

Published July 18, 2022

Key Messages

  • CADTH recommends that Breyanzi should be reimbursed by public drug plans for the treatment of patients with large B-cell lymphoma (LBCL) if certain conditions are met.
  • Breyanzi should only be covered to treat patients who have LBCL and have received at least 2 previous treatments that have not worked or have stopped working, as determined by a specialist.
  • Breyanzi should only be reimbursed if patients have not already been treated with a chimeric antigen receptor (CAR) T-cell therapy, are in relatively good health to tolerate the treatment, is prescribed and administered by specialists and trained personnel in dedicated centres, and if the cost of Breyanzi is reduced.